Brean Capital Boosts Onyx Pharma (ONXX) Price Target to $160
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Bidding for Onyx Pharma (ONXX) Done? Not Likely...
July 3, 2013 7:38 AM EDTOnyx Pharmaceuticals (Nasdaq: ONXX) recently surged on disclosure that Amgen (Nasdaq: AMGN) approachd the company with a $120 per share takeover offer. Despite shares being up 13 percent over the bid and 56 percent since the close last Friday, is... More
Maxim Group Downgrades Onyx Pharmaceuticals (ONXX) to Hold
July 1, 2013 11:18 AM EDTMaxim Group downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $86.82 yesterday, with a 52 week range of $63.00-$101.57.... More
Leerink Swann Raies Onyx (ONXX) Price Target to $140
July 1, 2013 9:34 AM EDTLeerink Swann today maintained an Outperform on Onyx Pharmaceuticals (NASDAQ: ONXX) and raised its price target to $140.00 (from $112). The change follows news of a $120 bid from Amgen (Nasdaq: AMGN).
Commenting, analyst Howard Liang said, "We see a... More
Onyx Pharma (ONXX) Reports $120/Share Bid from Amgen (AMGN); Hires Advisor
July 1, 2013 6:24 AM EDTOnyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. (Nasdaq: AMGN) to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. The Board of Directors of Onyx had evaluated the proposal made by Amgen with the assistance of its financial and legal advisors and concluded that... More
